- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.12.25 | Lyell Immunopharma pops on recent ASH data, immunotherapy expansion | 4 | Seeking Alpha | ||
| LYELL IMMUNOPHARMA Aktie jetzt für 0€ handeln | |||||
| 07.12.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition | 2 | GlobeNewswire (USA) | ||
| 05.12.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Lyell Immunopharma reports Q3 results | 3 | Seeking Alpha | ||
| 12.11.25 | Lyell Immunopharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11.25 | Lyell Immunopharma buys exclusive global rights to colorectal cancer drug | 1 | Seeking Alpha | ||
| 10.11.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer | 128 | GlobeNewswire (Europe) | LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal... ► Artikel lesen | |
| 10.11.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11.25 | Lyell Immunopharma: Vielversprechende Daten zu dualer CAR-T-Zelltherapie bei Lymphomen | 1 | Investing.com Deutsch | ||
| 03.11.25 | Lyell Immunopharma, Inc: Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition | 2 | GlobeNewswire (USA) | ||
| 03.11.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 26.09.25 | Lucid Capital Markets initiates Lyell Immunopharma stock with Buy rating | 2 | Investing.com | ||
| 16.09.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08.25 | Lyell Immunopharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.08.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 | 389 | GlobeNewswire (Europe) | Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the PiNACLE... ► Artikel lesen | |
| 12.08.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.06.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma | 216 | GlobeNewswire (Europe) | LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with... ► Artikel lesen | |
| 09.06.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments | 250 | GlobeNewswire (Europe) | Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary... ► Artikel lesen | |
| 13.05.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 | 300 | GlobeNewswire (Europe) | Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory... ► Artikel lesen | |
| 15.04.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma | 232 | GlobeNewswire (Europe) | RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or refractory large B-cell lymphoma.RMAT designation recognizes... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,034 | -7,57 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| AMGEN | 294,95 | +0,20 % | Amgen (AMGN): Ausbruch geglückt - Warum Trader jetzt die Marke von 345 USD genau im Auge behalten. | Perfekte Einstiegschance nach dem Pullback? Rückblick Amgen ist ein führendes Biotechnologieunternehmen und setzt stark auf Medikamente wie MariTide (Gewichtsverlust-Kandidat), das direkt mit den Produkten... ► Artikel lesen | |
| BIOGEN | 145,05 | +0,55 % | FDA Grants Priority Review To Eisai And Biogen's SBLA For LEQEMBI Subcutaneous Autoinjector | WESTON (dpa-AFX) - Eisai Co., Ltd. (ESALY, ESALF, 4523.T) and Biogen Inc. (BIIB) announced that the U.S. Food and Drug Administration has accepted for review Eisai's Supplemental Biologics License... ► Artikel lesen | |
| EDITAS MEDICINE | 1,779 | +2,36 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| GALAPAGOS NV | 29,260 | +1,32 % | Galapagos NV: Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities | Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has... ► Artikel lesen | |
| IMMATICS | 8,250 | +0,86 % | Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress | IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor... ► Artikel lesen | |
| AUTOLUS THERAPEUTICS | 1,180 | +0,85 % | Autolus Therapeutics plc - 8-K, Current Report | ||
| IGM BIOSCIENCES | 1,080 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.08.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 14.08.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.08.2025.ISIN NameCA87168M1068 SYNEX... ► Artikel lesen | |
| TANGO THERAPEUTICS | 12,100 | +3,60 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen | |
| TSCAN THERAPEUTICS | 1,150 | +1,77 % | TScan Therapeutics, Inc.: TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition | Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up... ► Artikel lesen | |
| QIAGEN | 45,395 | -2,23 % | Qiagen: Neue Spekulationen | Bei Qiagen gibt es erneut Übernahmegerüchte. Angeblich werden strategische Optionen, darunter auch ein Verkauf, geprüft. Demnach sondiert der Aufsichtsrat das Interesse von möglichen Käufern. Es soll... ► Artikel lesen | |
| BIONTECH | 100,30 | +1,11 % | BioNTech: FDA gewährt Fast-Track-Status für BNT113 | Die BioNTech SE hat von der U.S. Food and Drug Administration (FDA) den Fast-Track-Status für den mRNA-Krebsimmuntherapie-Kandidaten BNT113 erhalten. Die Zulassungserleichterung bezieht sich auf die... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,390 | +4,04 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| BIOMX | 7,500 | +77,73 % | Morning Market Movers: Nuwellis, BiomX, Brand Engagement Network, Blaize Holdings See Big Swings | WOONSOCKET (dpa-AFX) - At 7:02 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 306,24 | +4,15 % | Piper Sandler bekräftigt "Overweight"-Rating für Praxis Precision Medicines |
LYELL IMMUNOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,17 % bei einem Aktienkurs von 25,430 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYELL IMMUNOPHARMA INC finden Sie auf Wallstreet Online.